期刊文献+

熊去氧胆酸治疗老年原发性胆汁性肝硬化的临床研究

Clinical study of the treatment with Ursodeoxycholic acid in the elderly patients with primary biliary cirrhosis
下载PDF
导出
摘要 目的探讨老年原发性胆汁肝硬化(PBC)的临床特征、诊断和治疗效果。方法将66例诊断为PBC的病人分为老年组40例,中年组26例,比较两组的临床表现、生化免疫指标(碱性磷酸酶:ALP、谷氨酰转肽酶:GGT、抗线粒体抗体:AMA)。两组病例均给予口服熊去氧胆酸(UDCA:优思弗)治疗,服药8W后比较疗效。结果90%病人因体检发现ALP、GGT升高就诊,治疗前两组患者的ALP、GGT升高程度差异无统计学意义(P〉0.05)。非特异性皮肤瘙痒是老年PBC患者的主要表现,中年组患者中88.5%无症状,明显高于老年组的37.5%;口服优思弗8W后,两组ALP、GGT均较治疗前明显程度降低(P〈0.05)。老年组中3例肝硬化患者服用优思弗后,其症状、体征及ALP、GGT均无改善,2例死亡。服药后两组患者乏力、皮肤瘙痒症状均无改善,影像学也无变化。结论:(1)PBC早期缺乏特异症状;(2)AMA对PBC诊断有重要意义,ALP、GGT的升高早于黄疸、肝肿大出现。(3)应重视体检中无法解释的ALP、GGT异常升高。(4)UDCA对早期原发性胆汁肝硬化疗效满意。(5)老龄可能是影响PBC患者预后的因素之一。 Objective To study the clinical features, the ways of diagnosis and the therapeutic outcome in elderly patients with primary biliary cirrhosis (PBC). Methods 66 patients diagnosesd as PBC were divided into 2 groups: 40 cases in elderly group, 26 cases in middle-aged group. Their clinical features and the levels of serum ALP, GGT, serum AMA were evaluated and compared. All patients took UDCA (Ursodeoxycholic acid). The therapeutic effect were assessed and compared after taking drugs for 8 weeks. Results 90% patients went to the clinic because of increase in the levels of ALP and GGT. There was no significant difference in the increased levels of ALP and GGT between the 2 groups (P 〉 0.05). Unspecific skin ichy was the main symptom in elderly patients. 88.5 % patients in the middle-aged group had no symptoms, much more than that in the elderly group (37.5 %). The levels of ALP and GGT were significantly decreased in both groups after taking UDCA for 8 weeks. The 3 cases with liver cirrhosis had no improvement either in symptoms or in laboratory test after taking UDCA for 8 weeks. Conclusions There' s no specific symptoms or signs in the early stage of PBC. AMA is an important factor in the diagnosis of PBC. Patients always show high ALP and GGT before jaundice, ascites or liver enlargement. Unreasonable ascending of ALP and GGT should be paid more attention. UDCA is useful to the patients with PBC in early stage, but no response to those in advanced stage. Age may be one of the factors for the prognosis of PBC.
出处 《老年医学与保健》 CAS 2011年第6期346-348,共3页 Geriatrics & Health Care
关键词 老年 原发性胆汁性肝硬化 熊去氧胆酸 Elderly Primary biliary cirrhosis Ursodeoxycholic acid
  • 相关文献

参考文献9

  • 1Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the study of liver diseases practice guidelines [J]. Hepatology, 2000, 31 (4): 1005-1013.
  • 2姚光弼.重视原发性胆汁性肝硬化的临床研究[J].中华肝脏病杂志,2002,10(5):325-326. 被引量:33
  • 3MetcalfJV, MitchisonHC, Palmer JM, etal. Natural history of early primary biliary cirrhosis [J]. Lancet, 1996, 348 (9039): 1399-1402.
  • 4Mattalia A, Quaranta S, Leung PS, et al. Characterization of antimitochondrial antibodies in healthy adults [J]. Hepato- logy, 1998, 27 (3): 656-661.
  • 5Shibata M, Onozuka Y, Morizane T, et al. Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture [.!]. J Gastroenterol, 2004, 39(3): 255-259.
  • 6Prince MI, Chetw ynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large populati on based cohort [J]. Gut, 2004, 53 (6): 865-870.
  • 7Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic pa- tients followed for 24 years [J]. J Hepatol, 1994, 20 (6): 707-713.
  • 8Springer J, Cauch-Dudek K, O' Rourke K, et al. Asymptomatic primary biliary cirrhosis. A study of its natural history and prog- nosis [J]. Am JGastroenterol, 1999, 94 (1): 47-53.
  • 9张福奎,张影,王宝恩.原发性胆汁性肝硬化的自然史[J].肝脏,2009,14(3):251-253. 被引量:5

二级参考文献21

  • 1Metcalf JV,Mitchison HC,Palmer JM,et al.Natural history of early primary biliary cirrhosis.Lancet,1996,348:1399-1402.
  • 2Gershwin ME,Ansari AA,Mackay IR,et al.Primary biliary cirrhosis:an orchestrated immune response against epithelial cells.Immunol Rev,2000,174:210-225.
  • 3Lazaridis KN,Juran BD,Boe GM,et al.Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis.Hepatology,2007,46:785-792.
  • 4O′Brien C,Joshi S,Feld JJ,et al.Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis.Hepatology,2008,48:550-556.
  • 5Prince MI,Chetwynd A,Craig WL,et al.Asymptomatic primary biliary cirrhosis:clinical features,prognosis,and symptom progression in a large population based cohort.Gut,2004,53:865-870.
  • 6Springer J,Cauch-Dudek K,O′Rourke K,et al.Asymptomatic primary biliary cirrhosis:a study of its natural history and prognosis.Am J Gastroenterol,1999,94:47-53.
  • 7Jones DEJ,Bhala N,Burt J,et al.Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort.Gut,2006,55:536-541.
  • 8Talwalkar JA,Souto E,Jorgensen RA,et al.Natural history of pruritus in primary biliary cirrhosis.Clin Gastroenterol Hepatol,2003,1:297-302.
  • 9Laurin JM,DeSotel CK,Jorgensen RA,et al.The natural history of abdominal pain associated with primary biliary cirrhosis.Am J Gastroenterol,1994,89:1840-1843.
  • 10Prince M,Chetwynd A,Newman W,et al.Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis:follow-up for up to 28 years.Gastroenterology,2002,123:1044-1051.

共引文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部